SeaStar Medical reports FY2024 net loss $24.8M; first product revenue $0.1M from QUELIMMUNE launch

SeaStar Medical Holding Corp

Net loss for 2024 was $24.8M ($6.63 per share) vs $26.2M ($30.26) in 2023.
First net revenue of $0.1M from QUELIMMUNE pediatric AKI therapy approved via HDE in Q1 2024.
NEUTRALIZE AKI pivotal trial enrolled 94 of 200 patients; added 14 sites in 2024.
Raised ~$31M in capital and reduced debt; $6M registered direct financing completed Feb 2025.
Cash and short-term investments $1.8M at Dec 31, 2024, before February financing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.